13 (2.4) 0.005 eFigure 2. Diagrams of the association between increased fat body mass (FBM) and vertebral fractures. Legend: In the aromatase inhibitor (AI)-naïve patients (A), increased FBM is associated with bone quality deterioration due to increased inflammation proteins such as interleukin 6 (IL6), tumor necrosis factor α (TNFα), © 2019 Pedersini R et al. JAMA Network Open 14 increased levels of adiponectin and leptin, insulin and parathyroid hormone (PTH), and decreased levels of 25-OH vitamin D. This negative effect is compensated by higher bone mineral density due to elevated estrogen levels as a consequence of aromatase activity. In the AI-treated patients (B), the loss of estrogens due to aromatase inhibition results in lower BMD and this contributes to increase the fracture risk favored by bone quality deterioration. +, positive effect, -negative effect.
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